



ADVISED IMPLANET ON ITS €5.5M FUNDRAISING

February 2024



Implanet is a medical technology company that produces premium implants for orthopedic surgery. Its business is centered around an innovative solution designed to improve the treatment of spinal pathologies, JAZZ[®], which is complemented by the range of products offered by the company Orthopaedic & Spine Development, acquired in May 2021. Protected by 4 families of international patents, JAZZ[®] has received 510(k) regulatory clearance from the FDA in the United States, CE marking for Europe, and ANVISA authorization in Brazil.

In June 2022, IMPLANET entered into a commercial, strategic, and financial partnership with the Chinese group SANYOU MEDICAL, the second-largest Chinese manufacturer of medical devices for spine surgery. This partnership was notably materialized by SANYOU MEDICAL's acquisition of a 30% stake in IMPLANET in October 2022, which was later increased to 41% in March 2023 following the exercise of share subscription warrants.

This partnership aims to distribute products manufactured by IMPLANET in China and to develop a completely new full range of a hybrid fixation system by pooling their expertise and research and development resources.

IMPLANET achieved a turnover of €7.4 million in 2023.

Following an initial issuance of shares with share subscription warrants in October 2022 amounting to €5.3 million, ATOUT CAPITAL assisted IMPLANET in structuring a new capital increase of €5.5 million. This operation, which maintained the preferential subscription right, allowed SANYOU MEDICAL to increase its stake in IMPLANET's capital to 74.6%.

Thanks to this operation, IMPLANET has the means to continue its investments and asserts itself as a reference player in spine surgery, both in France and internationally, while consolidating its financial position.